<- Go Home
Consun Pharmaceutical Group Limited
Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; Iopamidol injections for neuroradiology, angiography, and urography; and ultrasonic microbubble contrast agent products. It also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yuan, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis; Gyn Antidysmenorrheic tablets for irregular menstruation, an irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion to treat staphylococcus aureus, candida albicans, and escherichia coli in the feminine vaginal. The company offers bone-setting liquid; Yunxiang analgesic tincture to treat rheumatism, common cold, headache, stomachache, cardiodynia, and pain in the gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; Shiduqing capsules and tablets, and Paeonol ointment for skin disease; and hepatobiliary products, such as Jigucao, Compound Jigucao, and Qinggan tablets, as well as Jigucao Ganyan and Wujun Zhidan granules. It also provides gastroenterology, tonics, and other medicines. The company was founded in 1997 and is headquartered in Guangzhou, the People’s Republic of China.
Market Cap
HKD 8.9B
Volume
2.3M
Cash and Equivalents
HKD 2.9B
EBITDA
HKD 1.0B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
HKD 2.2B
Profit Margin
75.56%
52 Week High
HKD 10.76
52 Week Low
HKD 4.82
Dividend
5.15%
Price / Book Value
2.16
Price / Earnings
9.78
Price / Tangible Book Value
2.31
Enterprise Value
HKD 5.6B
Enterprise Value / EBITDA
5.38
Operating Income
HKD 975.0M
Return on Equity
22.07%
Return on Assets
10.73
Cash and Short Term Investments
HKD 3.9B
Debt
HKD 267.2M
Equity
HKD 4.4B
Revenue
HKD 3.0B
Unlevered FCF
HKD 697.3M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium